Saphris (Asenapine): How This Antipsychotic Works and When Telehealth Is Enough

Last updated: August 21, 2026

Saphris (asenapine) is a second-generation (atypical) antipsychotic used for schizophrenia in adults and for bipolar I disorder (acute manic or mixed episodes in adults and adolescents, plus maintenance and adjunct options in adults). Unlike most oral antipsychotics, brand Saphris is a sublingual tablet that dissolves under the tongue. You do not swallow it, and you avoid food and drink for 10 minutes after it dissolves. This guide covers how asenapine works, label dosing ranges, side effects and the boxed dementia warning, drug interactions, the Secuado patch at a high level, and when online psychiatry may be enough for evaluation and follow-up.

See if online depression or mood care may be a fit →

Browse Klarity condition pages →

What is Saphris (asenapine)?

Asenapine is an atypical antipsychotic. According to MedlinePlus (last revised 11/15/2025), it is used to treat symptoms of schizophrenia and bipolar I disorder. It works by changing the activity of certain natural substances in the brain. Brand name for the sublingual tablets: Saphris®.

NAMI describes asenapine as a second-generation antipsychotic (SGA) that rebalances dopamine and serotonin to improve thinking, mood, and behavior. Forms NAMI lists:

• Saphris® sublingual tablets: 2.5 mg, 5 mg, 10 mg
• Secuado®: extended-release transdermal patch (3.8 mg, 5.7 mg, 7.6 mg per 24 hours)

Generic asenapine sublingual tablets may be available depending on your pharmacy and plan. Whether brand or generic is preferred depends on formulary design. The patch is a separate product with its own application rules; this article focuses on oral Saphris for patient education and notes Secuado only at a high level.

How asenapine works

Asenapine is discussed clinically as blocking dopamine D2 and serotonin 5-HT2A receptors (among other receptor effects). That profile can reduce hallucinations, delusions, and disorganized thinking in schizophrenia, and it is also labeled for bipolar I mania and related uses. It still carries the class warnings of atypical antipsychotics and needs medical supervision.

MedlinePlus notes that asenapine may help control symptoms but does not cure the condition. Continue the medicine even when you feel well unless your prescriber changes the plan. Do not stop suddenly without guidance.

NAMI’s timing summary:

• Hallucinations, disorganized thinking, and delusions may improve in the first 1-2 weeks
• Motivation and social drive can take at least 1-2 weeks to improve
• It may take 2-3 months before you get the full benefit

FDA-labeled uses (Saphris sublingual tablets)

Per the DailyMed SAPHRIS (asenapine) sublingual tablet prescribing information (revised January 2025; recent major changes to Warnings and Precautions 01/2025), Saphris is an atypical antipsychotic. NAMI summarizes FDA-approved uses that match the label’s clinical program:

• Schizophrenia in adults
• Acute treatment of manic or mixed episodes of bipolar I disorder in adults (alone or with lithium or valproate)
• Acute treatment of manic episodes of bipolar I disorder in pediatric patients ages 10-17 (monotherapy)
• Maintenance treatment of bipolar I disorder (adults, per clinical program / NAMI summary)

Your clinician matches the indication, age, formulation (sublingual vs patch), and monitoring plan to your history. Off-label uses exist in practice; those decisions belong in a documented clinical relationship, not in a blog post.

Typical dosing (label ranges)

Always follow the dose on your prescription. DailyMed highlights dosing table patterns for sublingual tablets:

• Schizophrenia, adults (acute): start and recommended often 5 mg twice daily; maximum 10 mg twice daily
• Schizophrenia, adults (maintenance): start often 5 mg BID; recommended range often 5-10 mg BID; max 10 mg BID
• Bipolar mania, adults (acute and maintenance monotherapy): start and recommended often 5-10 mg BID; max 10 mg BID
• Bipolar mania, ages 10-17 (monotherapy): start 2.5 mg BID; range often 2.5-10 mg BID; max 10 mg BID (escalate carefully)
• Bipolar mania, adults (adjunct to lithium or valproate): start often 5 mg BID; recommended 5-10 mg BID; max 10 mg BID

DailyMed schizophrenia section notes: the recommended dose is often 5 mg twice daily. In short-term trials, 10 mg BID did not clearly add benefit vs 5 mg BID but increased certain adverse reactions. If tolerated, the dose can increase to 10 mg BID after one week. Safety above 10 mg BID has not been evaluated in those studies.

For pediatric bipolar mania, DailyMed describes a stepwise path: 2.5 mg BID start → after 3 days may go to 5 mg BID → after 3 more days may go to 10 mg BID when appropriate. Skipping the escalation can raise dystonia risk in that age group.

NAMI states the usual sublingual tablet dose range is about 5 mg to 10 mg (taken twice daily in practice for most labeled regimens). For Secuado, NAMI notes a typical start of 3.8 mg/24 hours, with possible increases to 5.7 or 7.6 mg/24 hours after one week under clinician guidance.

Tablet strengths on the label: 2.5 mg, 5 mg, and 10 mg (black cherry flavor sublingual tablets).

How to take Saphris (sublingual technique matters)

From MedlinePlus and DailyMed administration instructions:

• Take twice a day at about the same times
• Keep tablets in the original packaging until the dose; handle with dry hands
• Place the tablet under the tongue and let it dissolve completely (usually within seconds)
• Do not split, crush, chew, or swallow the tablet
• Do not eat or drink for 10 minutes after the tablet dissolves (food or drink too soon can cut absorption)
• Do not take more or less than prescribed
• If you miss a dose, take it when you remember unless it is almost time for the next dose; do not double up

That 10-minute no food/drink rule is one of the most practical differences between Saphris and tablets you swallow with water. Ask your pharmacist to walk through the blister technique if the packaging feels confusing the first week.

For Secuado (high level only): NAMI notes apply every 24 hours to hip, abdomen, upper arm, or upper back; rotate sites; do not cut patches; showering is generally allowed, but swimming/bathing has not been fully evaluated the same way; avoid heating pads on the application site.

Side effects and serious risks

Boxed warning (dementia-related psychosis): Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Saphris is not approved for dementia-related psychosis. MedlinePlus also notes a greater chance of stroke or ministroke in older adults with dementia during antipsychotic treatment.

Common side effects MedlinePlus lists (tell your clinician if severe or persistent): dry mouth, nausea, increased appetite or weight gain, increased saliva, taste change, numbness in lips or mouth, dizziness or balance trouble, tiredness, restlessness or urge to keep moving.

NAMI’s common side-effect summary includes drowsiness, insomnia, restlessness, fatigue, extrapyramidal symptoms, headache, weight gain, increased glucose, cholesterol abnormalities, and temporary numbness of the mouth or tongue. Patch users may get local skin reactions; rotating sites can help.

Serious risks (seek urgent care if they occur) include, from MedlinePlus and NAMI/label class warnings:

• Allergic reactions (rash, hives, swelling, trouble breathing or swallowing)
• Neuroleptic malignant syndrome (fever, stiff muscles, confusion, sweating, fast or irregular heartbeat)
• Severe muscle spasm (for example neck dystonia)
• Uncontrollable movements (tardive dyskinesia risk with long-term antipsychotics)
• Falls, seizures, signs of infection that may relate to low white blood cells
• Metabolic changes: high blood sugar, weight gain, lipid changes
• Orthostatic hypotension (dizziness when standing)
• QT prolongation and related heart-rhythm risk (your clinician may order an ECG when risk factors stack)
• Hyperprolactinemia (missed periods, breast milk production, sexual side effects; long-term bone risk if prolactin stays high)
• Impaired heat regulation; stay hydrated and avoid overheating

MedlinePlus advises regular weight checks and keeping lab and clinic appointments. Asenapine can cause drowsiness; do not drive or operate machinery until you know how you respond.

Drug interactions and cautions

Tell every clinician and pharmacist you take asenapine. NAMI highlights several practical interaction themes:

• Asenapine may block effects of some Parkinson disease medicines (for example levodopa combinations, pramipexole, ropinirole)
• Blood-pressure medicines can add to dizziness and fall risk
• Asenapine may increase levels and effects of paroxetine (Paxil)
• Other QT-prolonging drugs raise heart-rhythm concern (examples NAMI lists include certain antipsychotics such as Fanapt, Invega, Seroquel, Geodon, and some antiarrhythmics such as amiodarone, sotalol, quinidine)
• Fluvoxamine and ciprofloxacin may increase asenapine levels and effects

Avoid alcohol and illicit drugs; they can worsen sedation and undercut benefit. MedlinePlus asks you to review surgery (including dental) plans with the team, and to share history of diabetes, QT issues, low white cells, seizures, liver disease, swallowing problems, and pregnancy or breastfeeding plans. NAMI states breastfeeding is generally not recommended while taking asenapine; third-trimester antipsychotic exposure can cause EPS or withdrawal signs in newborns that need monitoring.

Severe hepatic impairment can be a special-population issue on antipsychotic labels; your prescriber decides whether asenapine is appropriate if liver disease is present. Do not self-adjust dose for “milder” side effects without clinical guidance.

Saphris vs other atypical antipsychotics

People comparing options often look at sister guides on Klarity:

• Abilify (aripiprazole)
• Vraylar (cariprazine)
• Seroquel (quetiapine)
• Latuda (lurasidone)
• Zyprexa (olanzapine)
• Risperdal (risperidone)
• Geodon (ziprasidone)
• Invega (paliperidone)
• Fanapt (iloperidone)
• Rexulti (brexpiprazole)
• Caplyta (lumateperone)

What often sets Saphris apart in day-to-day use is the sublingual route and the 10-minute nothing-by-mouth window, plus oral numbness or taste change that many people notice early. Choice among atypicals still depends on diagnosis, prior response, metabolic and movement risk, QT risk, pregnancy plans, and how well you can stick to the administration rules.

When telehealth may be enough

Online psychiatry can be a strong fit for many people who need evaluation for mood or psychotic symptoms, medication education, dose follow-up, and side-effect monitoring when they are medically stable. Klarity connects patients with licensed clinicians in a network of 2,000+ providers. Medicare policy context from HHS telehealth policy updates: behavioral and mental health telehealth has broader permanent coverage pathways than many non-behavioral services, and certain in-person visit requirements for mental health telehealth remain waived through December 31, 2027 under current federal flexibilities (confirm your plan’s rules).

Telehealth is not enough when you need emergency care, when there is active medical instability, when labs or ECG cannot be arranged safely, or when a clinician decides in-person assessment is required. Acute mania with safety risk, severe psychosis with inability to engage by video, suspected NMS, severe allergic reaction, or suicidal crisis need local emergency resources first.

If you are in crisis, call or text 988 (Suicide & Crisis Lifeline) or use local emergency services.

Insurance, cost, and next steps

Whether a plan may cover Saphris or generic asenapine depends on formulary tier, prior authorization, step therapy, and your specific benefit design. Coverage varies by plan. Verify benefits before you assume a copay. Klarity does not guarantee that any insurer will cover a medication or visit.

Disclaimer: This article is educational and is not medical advice, a diagnosis, or a treatment plan. Medication decisions require a licensed clinician who knows your history. Always read the Medication Guide that comes with your prescription and follow your prescriber’s instructions.

Check if online mental health care may work for you →

Explore conditions Klarity treats →

Frequently asked questions

Is Saphris the same as asenapine?

Saphris is a brand name for asenapine sublingual tablets. Asenapine is the generic drug name. Secuado is a separate brand for an asenapine skin patch.

Can I swallow Saphris with water?

No. DailyMed and MedlinePlus instruct you to place it under the tongue and let it dissolve. Swallowing it can reduce how much medicine you absorb. Wait 10 minutes before eating or drinking.

How long does Saphris take to work?

NAMI notes early psychosis symptom change can start in 1-2 weeks, with fuller benefit often by 2-3 months. Your timeline may differ.

Does Saphris cause weight gain?

Weight gain and metabolic changes are known class and drug risks. MedlinePlus lists increased appetite and weight gain among possible effects. Your clinician may monitor weight, glucose, and lipids.

Is Saphris approved for dementia-related psychosis?

No. The FDA boxed warning states increased mortality risk in elderly patients with dementia-related psychosis, and Saphris is not approved for that use.